IKT

Inhibikase Therapeutics Inc

• TipRanks·08/14 15:30

  Analysts Are Bullish on Top Healthcare Stocks: Evotec AG (EVO), Taysha Gene Therapies (TSHA)

• TipRanks·08/13 06:01

  Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth

• Benzinga·08/11 20:16

  Inhibikase Therapeutics Q2 EPS $(0.11), Inline

• Dow Jones·08/11 20:01

  Press Release: Inhibikase Therapeutics Announces -2-

• Dow Jones·08/11 20:01

  Press Release: Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

• TipRanks·07/31 10:45

  Analyst Reiterates Buy on IKT, Maintaining $8 Price Target Amid Regulatory Progress and Phase 3 PAH Trial Momentum

• TipRanks·07/29 20:39

  Inhibikase Therapeutics Executes Pre-Funded Warrant Exchange

• TipRanks·07/28 10:50

  Analysts Are Bullish on These Healthcare Stocks: The Ensign Group (ENSG), Stryker (SYK)

• TipRanks·07/23 13:02

  Inhibikase Gains FDA Orphan Drug Status for IKT-001

• TipRanks·07/23 12:16

  Inhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA

• Benzinga·07/23 12:03

  Inhibikase Therapeutics Says FDA Grants Orphan Drug Designation To Its Lead Product Candidate IKT-001, Prodrug Of Imatinib Mesylate, For Treatment Of PAH

• Benzinga·07/21 12:01

  Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

• Seeking Alpha·07/19 19:10

  Oppenheimer’s ‘best of the best’ momentum list: NVDA, LRCX and more

• TipRanks·07/16 21:05

  Inhibikase Therapeutics’ treatment of PAH granted FDA orphan designation

• TipRanks·07/15 08:05

  Inhibikase raises $50M to fund PAH program